PAR vs SHUKRAPHAR: Stock Comparison
PAR shows a lower P/E and a higher net margin, while SHUKRA PHARMACEUTICALS L shows a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
PAR leads 6; SHUKRAPHAR leads 3 of 9
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | PAR | SHUKRAPHAR |
|---|---|---|
| Sector | Healthcare | — |
| Industry | Pharmaceuticals | — |
Price
| Metric | PAR | SHUKRAPHAR |
|---|---|---|
| Live Price | ₹164.95 | ₹54.36 |
| Day Change | -1.96% | -0.44% |
| Volume | 7.26 L | 10.95 L |
| 52-Week High | ₹180 | ₹58.2 |
| 52-Week Low | ₹78.05 | ₹40.06 |
| Distance from 52W High | -8.36% | -6.6% |
Valuation
| Metric | PAR | SHUKRAPHAR |
|---|---|---|
| Market Cap | ₹163 Cr | ₹0 Cr |
| P/E Ratio | 8.55x | 63.03x |
| P/B Ratio | 0x | 21.83x |
| EPS | ₹3.83 | ₹0.34 |
| Book Value | ₹91.01 | ₹2.05 |
| Dividend Yield | 0% | 0.02% |
Growth
| Metric | PAR | SHUKRAPHAR |
|---|---|---|
| Revenue Growth (TTM YoY) | -12.2% | 0% |
| EPS Growth (TTM YoY) | -48.5% | 0% |
| Qtr Sales Growth | 59.51% | 0% |
| Qtr Profit Growth | 452.1% | 15.98% |
Profitability & Leverage
| Metric | PAR | SHUKRAPHAR |
|---|---|---|
| ROE | 11.71% | — |
| ROCE | 18.83% | — |
| Net Margin | 12.65% | 0% |
| Operating Margin | 16.81% | — |
| Debt to Equity | 0x | — |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | PAR | SHUKRAPHAR |
|---|---|---|
| Promoter Holding | 73.41% | 50.96% |
| FII Holding | 0% | 0% |
| DII Holding | 0.09%▲ 0.09 pp | 0.11% |
| Public Holding | 26.51%▼ 0.08 pp | 48.92%▼ 0.01 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: PAR and SHUKRA PHARMACEUTICALS L.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.